1. AMDS Products, events and issues.
Dr Vincent Habiyambere
TCO/AMDS – HIV Department
WHO
Geneva, 12 June 2015

2. HIV and hepatitis @ HIV/WHO
World Health Organization
HIV and hepatitis @ HIV/WHO
5 December, 2018
New ART guidelines are expected in July 2015:
Likely no changes to current preferred regimens.
DTG and DRV under discussion as alternatives in first and second line, respectively. TAF not yet available, and therefore not included.
Expansion of treatment indications to ""Treat All" under discussion.
Increased emphasis on supply continuity as part of recommendations.
New Hep C guidelines are expected in Dec 2015: following inclusion of sofosbuvir and simeprevir, ledipasvir and daclatasvir are under consideration as part of preferred regimens. EOI and PQ are moving on hepatitis.
Consolidated HIV Strategic Information guidelines were released this month. Stock out of ARV drugs is one of the 10 global indicators.
New Consolidated HIV, hepatitis and STI strategy under development.
AMDS survives, part of SIP team after August 2015.

3. Products completed since last IPC Available
World Health Organization
5 December, 2018
GPRM :
TB transactions included
HIV transactions updated incl. Q1 2015
Interface updated
ARV regulatory status: 2015 update live on web
2014 PSM country profiles for > 70 countries

4. Products completed since last IPC Publication imminent, pending internal clearance (but can share)
2015 ARV APIs survey
Forecasts of ARV demand up to and uptake of new ARVs (DTG, TAF, RAL) up to 2024 (with MPP and CHAI)
Forecasts of demand for HIV diagnostics up to 2018
Specifications and quantification of essential HIV diagnostics.
POC EQA tool developed by WHO in collaboration with CDC

5. Ongoing work and planned events
World Health Organization
5 December, 2018
Work:
ARV and HIV diagnostic use survey (with GARPR) – ongoing
GPRM update and updated/dissemination of 2015 PSM Country Profiles – Q3
Report on access to ARVs and HIV diagnostics, for AIDS conference in Durban, July 2016
Planned events:
Satellite on PSM challenges, posters at 2015 AIDS conference
Annual AMDS partners meeting, tentatively Sept 2015
TWG meeting on ARV & diagnostic demand, Nov. 2015
Meeting with pharma and diagnostics producers on forecasts and related developments, Feb 2016

6. World Health Organization
Issues
World Health Organization
5 December, 2018
STOCK OUTS
In last month, South Africa, Mauritania, Congo, and Guinea had stock outs of ARVs, TB medicines and malaria medicines (Congo).
Lab stock outs are rarely reported, but a regular occurrence.
Emergency TA was provided with high transaction costs
We used CPP partners to solve the problem in Guinea
Congo was going to use DRC drugs and buy after our help in connecting with IDA, funds disbursement is delayed for procurement: so no effective order placed.
The CPPi has insufficient coverage, and is only a firefighting operation
We need a more systemic approach to prevent stock outs: role of Interagency Supply Chain Group (ISG)?

7. What IPC could do to prevent stock outs
World Health Organization
5 December, 2018
The current attention given to HIV, TB and malaria, incl. civil society pressure, offers an opportunity to re-open the discussion on the efficiency of health commodity supply chains and mobilize funding to fix the problems.
IPC should use this opportunity through:
Assessment of causes of stock out in selected countries, identify solutions, and publicize outcome to increase the SCM level on national & international agenda.
Document in a few low income countries what it takes to create an effectively operational SCM including LMIS not just for ARVs, but for all essential health commodities, to inform creation of planning templates.
Produce (or update if it exists already) normative guidance on the essential components of a functioning supply chains, including for LMIS, and technical guidance on how to plan and cost their development.
Country level collaboration between partners & nationals for a stronger SCM with a stronger government leadership.